RU97109913A - ORTHO-SUBSTITUTED BENZOILGUANIDINES, METHOD FOR PRODUCING THEM, THEIR APPLICATION AS A MEDICINE OR DIAGNOSTIC MEDICINES AND CONTAINING THEIR MEDICINE - Google Patents
ORTHO-SUBSTITUTED BENZOILGUANIDINES, METHOD FOR PRODUCING THEM, THEIR APPLICATION AS A MEDICINE OR DIAGNOSTIC MEDICINES AND CONTAINING THEIR MEDICINEInfo
- Publication number
- RU97109913A RU97109913A RU97109913/04A RU97109913A RU97109913A RU 97109913 A RU97109913 A RU 97109913A RU 97109913/04 A RU97109913/04 A RU 97109913/04A RU 97109913 A RU97109913 A RU 97109913A RU 97109913 A RU97109913 A RU 97109913A
- Authority
- RU
- Russia
- Prior art keywords
- atoms
- substituted
- phenyl
- ortho
- cycloalkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 13
- 238000004519 manufacturing process Methods 0.000 title claims 12
- 125000004432 carbon atoms Chemical group C* 0.000 claims 48
- AJDQRQQNNLZLPM-UHFFFAOYSA-N N-(diaminomethylidene)benzamide Chemical class NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 claims 18
- -1 biphenylyl Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 125000001624 naphthyl group Chemical group 0.000 claims 10
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 230000000302 ischemic Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000000056 organs Anatomy 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 206010002383 Angina pectoris Diseases 0.000 claims 1
- 206010003119 Arrhythmia Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 210000003414 Extremities Anatomy 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010000546 Metabolism disorder Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 1
- 230000000879 anti-atherosclerotic Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (18)
где R(1)-H, F, Cl, Br, I, CN, NO2, алкил с 1-8 С-атомами, алкокси с 1-8 С-атомами, циклоалкил с 3-8 С-атомами, циклоалкокси с 3-8 С-атомами или Xa-(СH2)b-(СF2)c-CF3; где Х кислород, сера или NR(9), a = 0 или 1, b = 0, 1 или 2, c = 0, 1, 2 или 3; R(9)-H, алкил с 1-4 С-атомами или -CdH2dR(6), где d = 0, 1, 2, 3 или 4, R(6)-циклоалкил с 3-8 С-атомами, фенил, бифенилил или нафтил, причем ароматические соединения фенил, бифенилил или нафтил не замещены или замещены 1-3 заместителями, выбираемыми из группы, состоящей из F, Cl, CF3, метила, метокси и NR(7)R(8), где R(7) и R(8) независимо друг от друга-Н или алкил с 1-4 С-атомами;
или R(1) -SR(10), -OR(10) или -CR(10)R(11)R(12), где R(10)-CfH2f-циклоалкил с 3-8 С-атомами в циклоалкильном кольце, гетероарил с 1-9 С-атомами или фенил, причем гетероарил и фенил не замещены или замещены 1-3 заместителями, выбираемыми из группы, состоящей из F, Cl, CF3, CH3, метокси, гидрокси, амино, метиламино и диметиламино, f = 0, 1 или 2, R(11) и R(12) независимо друг от друга определены как R(10), или водород, или алкил с 1-4 С-атомами;
или R(1)-фенил, нафтил, бифенилил или гетероарил с 1-9 С-атомами, последний связан через С- или N-атом кольца, которые соответственно не замещены или замещены 1-3 заместителями, выбираемыми из группы, состоящей из F, Cl, CF3, CH3, метокси, гидрокси, амино, метиламино и диметиламино;
или R(1) -SR(13), -OR(13), -NHR(13), -NR(13)R(14), -CHR(13)R(15), -C[R(15)R(16)OH] , -C[R(19)] = CHR(18), -C[R(20)R(21)]k-(CO)-[CR(22)R(23)]fR(24), где k = 0, 1, 2, 3 или 4, l = 0, 1, 2, 3 или 4, R(13) и R(14), одинаковые или различные, - (СН2)g-(СНОН)h-(CH2)i-(CHOH)kk-R(17) или -(CH2)g-O-(CH2CH2O)h-R(24), R(17)-водород или метил, g, h и i, одинаковые или различные, - 0, 1, 2, 3 или 4, kk - 1, 2, 3 или 4, R(15) и R(16), одинаковые или различные, -водород, алкил с 1-6 С-атомами или вместе с несущим их атомом углерода циклоалкил с 3-8 С-атомами, R(18)-фенил, который не замещен или замещен 1-3 заместителями, выбираемыми из группы, состоящей из F, Cl, CF3, метила, метокси и NR(25)R(26), R(25) и R(26)-Н или алкил с 1-4 С-атомами, или R(18)-гетероарил с 1-9 атомами углерода, который не замещен или замещен как фенил, или R(18)-алкил с 1-6 С-атомами, который не замещен или замещен 1-3 ОН, или R(18)-циклоалкил с 3-8 С-атомами, R(19)-R(23), одинаковые или различные, -водород или метил, R(24)-H, алкил с 1-6 С-атомами, циклоалкил с 3-8 С-атомами или -CmH2m-R(18), где m = 1, 2, 3 или 4;
один из двух заместителей R(2) и R(3)-O-CO-R(27), R(27)-алкил с 1-8 С-атомами, циклоалкил с 3-8 С-атомами, фенил, бифенилил, нафтил, пиридил или хинолинил, причем фенил, бифенилил, нафтил, пиридил или хинолинил не замещены или замещены 1-3 заместителями, выбираемыми из группы, состоящей из F, Cl, CF3, метила, метокси и NR(7)R(8), где R(7) и R(8) независимо друг от друга - водород или алкил с 1-4 С-атомами, причем всегда один из заместителей R(2) и R(3) определен как R(1);
R(4) и R(5) независимо друг от друга-водород, алкил с 1-4 С-атомами, алкокси с 1-4 С-атомами, F, Cl, Br, I, СN или -(СН2)n-(СF2)o, где n = или 1, o = 0 или 1, и их фармацевтически переносимые соли.1. Ortho-substituted benzoylguanidines of the formula I
where R (1) -H, F, Cl, Br, I, CN, NO 2 , alkyl with 1-8 C-atoms, alkoxy with 1-8 C-atoms, cycloalkyl with 3-8 C-atoms, cycloalkoxy with 3-8 C atoms or X a - (CH 2 ) b - (CF 2 ) c -CF 3 ; where X is oxygen, sulfur or NR (9), a = 0 or 1, b = 0, 1 or 2, c = 0, 1, 2 or 3; R (9) -H, alkyl with 1-4 C-atoms or -C d H 2d R (6), where d = 0, 1, 2, 3 or 4, R (6) -cycloalkyl with 3-8 C -atoms, phenyl, biphenylyl or naphthyl, the aromatic compounds phenyl, biphenylyl or naphthyl being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (7) R (8 ), where R (7) and R (8) are independently H or alkyl with 1-4 C atoms;
or R (1) -SR (10), -OR (10) or -CR (10) R (11) R (12), where R (10) -C f H 2f is cycloalkyl with 3-8 C atoms in the cycloalkyl ring, heteroaryl with 1-9 C atoms or phenyl, wherein heteroaryl and phenyl are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino, f = 0, 1 or 2, R (11) and R (12) are independently defined as R (10), or hydrogen, or alkyl with 1-4 C-atoms;
or R (1) -phenyl, naphthyl, biphenylyl or heteroaryl with 1-9 C-atoms, the latter being linked via the C- or N-atom of the ring, which are respectively unsubstituted or substituted by 1-3 substituents selected from the group consisting of F Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino;
or R (1) —SR (13), —OR (13), —NHR (13), —NR (13) R (14), —CHR (13) R (15), —C [R (15) R (16) OH], -C [R (19)] = CHR (18), -C [R (20) R (21)] k - (CO) - [CR (22) R (23)] f R (24), where k = 0, 1, 2, 3 or 4, l = 0, 1, 2, 3 or 4, R (13) and R (14), the same or different, - (CH 2 ) g - (CHOH) h - ( CH 2 ) i - (CHOH) kk -R (17) or - (CH 2 ) g -O- (CH 2 CH 2 O) h -R (24), R (17) -hydrogen or methyl, g, h and i, the same or different, are 0, 1, 2, 3 or 4, kk - 1, 2, 3 or 4, R (15) and R (16), the same or different, are hydrogen, alkyl from 1-6 C-atoms or together with a carbon atom carrying them, cycloalkyl with 3-8 C-atoms, R (18) -phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl , methoxy and NR (25) R (26), R (25) and R (26) -H or alkyl with 1-4 C-atoms, or R (18) -heteroaryl with 1-9 carbon atoms, which is unsubstituted or substituted as phenyl, or R (18) -alkyl with 1-6 C-atoms, which is unsubstituted or substituted by 1-3 OH, or R (18) -cycloalkyl with 3- 8 C-atoms, R (19) -R (23), identical or different, -hydrogen or methyl, R (24) -H, alkyl with 1-6 C-atoms, cycloalkyl with 3-8 C-atoms or - C m H 2m -R (18), where m = 1, 2, 3 or 4;
one of the two substituents R (2) and R (3) -O-CO-R (27), R (27) -alkyl with 1-8 C-atoms, cycloalkyl with 3-8 C-atoms, phenyl, biphenylyl, naphthyl, pyridyl or quinolinyl, wherein phenyl, biphenylyl, naphthyl, pyridyl or quinolinyl are unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (7) R (8) where R (7) and R (8) are independently hydrogen or alkyl with 1-4 C-atoms, and one of the substituents R (2) and R (3) is always defined as R (1);
R (4) and R (5) are independently hydrogen, alkyl with 1-4 C atoms, alkoxy with 1-4 C atoms, F, Cl, Br, I, CN or - (CH 2 ) n - (CF 2 ) o , where n = or 1, o = 0 or 1, and their pharmaceutically tolerated salts.
где R(1) - R(5) имеют указанное значение;
L обозначает легко замещаемую нуклеофильно-летучую группу, вступает во взаимодействие с гуанидином.5. The method of producing ortho-substituted benzoylguanidines according to claim 1, characterized in that the compound of formula II
where R (1) - R (5) have the indicated meaning;
L denotes an easily replaceable nucleophilic-volatile group, reacts with guanidine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19622370.9 | 1996-06-04 | ||
DE19622370A DE19622370A1 (en) | 1996-06-04 | 1996-06-04 | Ortho-substituted benzoylguanidines, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97109913A true RU97109913A (en) | 1999-05-10 |
RU2214397C2 RU2214397C2 (en) | 2003-10-20 |
Family
ID=7796095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97109913/04A RU2214397C2 (en) | 1996-06-04 | 1997-06-03 | Ortho-substituted benzoylguanidines and medicinal agent based on thereof |
Country Status (29)
Country | Link |
---|---|
US (1) | US6011063A (en) |
EP (1) | EP0811610B1 (en) |
JP (1) | JP4101904B2 (en) |
KR (1) | KR980002019A (en) |
CN (1) | CN1064956C (en) |
AR (1) | AR008761A1 (en) |
AT (1) | ATE209630T1 (en) |
AU (1) | AU723665B2 (en) |
BR (1) | BR9703440A (en) |
CA (1) | CA2206758C (en) |
CZ (1) | CZ289411B6 (en) |
DE (2) | DE19622370A1 (en) |
DK (1) | DK0811610T3 (en) |
ES (1) | ES2166487T3 (en) |
HR (1) | HRP970304B1 (en) |
HU (1) | HUP9700989A3 (en) |
ID (1) | ID17038A (en) |
IL (1) | IL120988A0 (en) |
MX (1) | MX9704094A (en) |
NO (1) | NO310188B1 (en) |
NZ (1) | NZ314973A (en) |
PL (1) | PL185757B1 (en) |
PT (1) | PT811610E (en) |
RU (1) | RU2214397C2 (en) |
SI (1) | SI0811610T1 (en) |
SK (1) | SK282628B6 (en) |
TR (1) | TR199700453A2 (en) |
TW (1) | TW429243B (en) |
ZA (1) | ZA974869B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
US6639077B2 (en) | 2000-03-23 | 2003-10-28 | Merck Frosst Canada & Co. | Tri-aryl-substituted-ethane PDE4 inhibitors |
MY123585A (en) | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
WO2001090076A1 (en) | 2000-05-25 | 2001-11-29 | Merck Frosst Canada & Co. | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
WO2002094823A1 (en) | 2001-05-24 | 2002-11-28 | Merck Frosst Canada & Co. | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyne-aryl phosphodiesterase-4 inhibitors |
DE60334781D1 (en) | 2002-03-12 | 2010-12-16 | Merck Sharp & Dohme | METABOTROPIC GLUTAMATE RECEPTOR-5 DI-ARYL SUBSTITUTED TETRAZOL MODULATORS |
GB0916163D0 (en) * | 2009-09-15 | 2009-10-28 | Shire Llc | Prodrugs of guanfacine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2107698T3 (en) * | 1993-02-20 | 1997-12-01 | Hoechst Ag | SUBSTITUTED BENZOILGUANIDINES, PROCEDURE FOR ITS PREPARATION, ITS USE AS A MEDICINAL PRODUCT, AS INHIBITORS OF NA + / H + CELL EXCHANGE OR AS A DIAGNOSTIC AGENT, AS WELL AS A CONTAINING MEDICINAL PRODUCT. |
DE4318756A1 (en) * | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them |
DE4422685A1 (en) * | 1994-06-29 | 1996-01-04 | Hoechst Ag | Ortho-amino-substituted benzoylguanidines, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them |
-
1996
- 1996-06-04 DE DE19622370A patent/DE19622370A1/en not_active Withdrawn
-
1997
- 1997-05-22 AT AT97108258T patent/ATE209630T1/en not_active IP Right Cessation
- 1997-05-22 DK DK97108258T patent/DK0811610T3/en active
- 1997-05-22 DE DE59705495T patent/DE59705495D1/en not_active Expired - Lifetime
- 1997-05-22 PT PT97108258T patent/PT811610E/en unknown
- 1997-05-22 ES ES97108258T patent/ES2166487T3/en not_active Expired - Lifetime
- 1997-05-22 SI SI9730284T patent/SI0811610T1/en unknown
- 1997-05-22 EP EP97108258A patent/EP0811610B1/en not_active Expired - Lifetime
- 1997-05-30 NZ NZ314973A patent/NZ314973A/en unknown
- 1997-06-02 TR TR97/00453A patent/TR199700453A2/en unknown
- 1997-06-02 CN CN971054797A patent/CN1064956C/en not_active Expired - Fee Related
- 1997-06-02 SK SK696-97A patent/SK282628B6/en unknown
- 1997-06-02 CZ CZ19971696A patent/CZ289411B6/en not_active IP Right Cessation
- 1997-06-02 AR ARP970102385A patent/AR008761A1/en unknown
- 1997-06-02 ID IDP971869A patent/ID17038A/en unknown
- 1997-06-02 TW TW086107502A patent/TW429243B/en active
- 1997-06-02 AU AU24650/97A patent/AU723665B2/en not_active Ceased
- 1997-06-03 RU RU97109913/04A patent/RU2214397C2/en not_active IP Right Cessation
- 1997-06-03 IL IL12098897A patent/IL120988A0/en unknown
- 1997-06-03 KR KR1019970022785A patent/KR980002019A/en not_active Application Discontinuation
- 1997-06-03 HR HR970304A patent/HRP970304B1/en not_active IP Right Cessation
- 1997-06-03 MX MX9704094A patent/MX9704094A/en unknown
- 1997-06-03 NO NO19972527A patent/NO310188B1/en not_active IP Right Cessation
- 1997-06-03 US US08/868,077 patent/US6011063A/en not_active Expired - Lifetime
- 1997-06-03 HU HU9700989A patent/HUP9700989A3/en unknown
- 1997-06-03 PL PL97320327A patent/PL185757B1/en not_active IP Right Cessation
- 1997-06-03 ZA ZA9704869A patent/ZA974869B/en unknown
- 1997-06-03 JP JP14439397A patent/JP4101904B2/en not_active Expired - Fee Related
- 1997-06-04 CA CA002206758A patent/CA2206758C/en not_active Expired - Fee Related
- 1997-06-04 BR BR9703440A patent/BR9703440A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5124147A (en) | Method for the treatment of endotoxic shock in a mammal | |
KR100236666B1 (en) | Compositions comprising a tramadol and any of codeine, oxycodone or hydrocodone, and their use | |
SU988190A3 (en) | Process for preparing hydantnoin | |
JPH10508858A (en) | Improved antiviral prodrug | |
EP0036145A1 (en) | An orally administered drug form comprising a polar bioactive agent and an adjuvant | |
EP0230893A2 (en) | Paramagnetic chelates | |
RU97109913A (en) | ORTHO-SUBSTITUTED BENZOILGUANIDINES, METHOD FOR PRODUCING THEM, THEIR APPLICATION AS A MEDICINE OR DIAGNOSTIC MEDICINES AND CONTAINING THEIR MEDICINE | |
KR20170113546A (en) | Processes for preparing oxathiazin―like compounds | |
KR960041152A (en) | Fluorophenyl-substituted alkenylcarboxylic acid guanidides, their preparation, their use as medicaments or diagnostic agents and medicaments containing them | |
JP2008545803A5 (en) | ||
KR950032129A (en) | Substituted bicyclic heteroaroylguanidines, methods for their preparation, their use as medicaments or diagnostic agents and medicaments containing the same | |
KR970015568A (en) | Substituted Benzoylguanidine, Method of Making the Same, Use thereof as a medicament or a diagnostic agent, and a pharmaceutical comprising the same | |
RU97109003A (en) | SUBSTITUTED 2-NAPTOYLGUANIDINES, METHOD FOR PRODUCING THEM AND MEDICINE ON THEIR BASIS | |
JP2005526138A5 (en) | ||
KR980002019A (en) | Ortho-substituted benzoylguanidine, its preparation as a preparation, medicament or diagnostic agent and medicament comprising the same | |
RU95115408A (en) | SUBSTITUTED BENZOILGUANIDINES, METHOD FOR PRODUCING THERE, CONTAINING THEIR MEDICINAL PRODUCT, METHOD OR MEANS FOR ITS PRODUCTION, METHOD OF TREATMENT | |
US5496850A (en) | Antimetastasis agent of malignant tumors | |
RU97109528A (en) | ORTO-SUBSTITUTED BENZOILGUANIDINES, THE WAY OF THEIR RECEPTION, THEIR USE AS A MEDICINE OR DIAGNOSTIC MEANS AND CONTAINING THEIR MEDICINE | |
RU2001104454A (en) | IMIDAZOLE DERIVATIVES WITH BIPHENYL SULPHONYL SUBSTITUTION, METHOD FOR PRODUCING THEM, USE AS A MEDICINAL PRODUCT OR A DIAGNOSTIC, AND ALSO CONTAINING THEIR MEDICINAL | |
US5830509A (en) | Microparticle complexes with 2-amino-1-phenylpropanol materials | |
RU97103361A (en) | ORTO-SUBSTITUTED BENZOILGUANIDINES, THE WAY OF THEIR RECEPTION, THEIR USE AS A MEDICINE OR DIAGNOSTIC MEANS AND CONTAINING THEIR MEDICINE | |
RU97102136A (en) | SUBSTITUTED GUANIDIDES OF THIOPHENYLALKENYL CARBONIC ACID, METHOD OF THEIR RECEIVING THEM, THEIR USE AS A MEDICINE OR DIAGNOSTIC MEANS AND CONTAINING THEIR MEDICINE | |
RU97103109A (en) | ORTO-SUBSTITUTED BENZOILGUANIDINES, THE WAY OF THEIR RECEPTION, THEIR USE AS A MEDICINE OR DIAGNOSTIC MEANS AND CONTAINING THEIR MEDICINE | |
EP3534954A1 (en) | Compounds for treatment of neurodegenerative diseases | |
CA1250838A (en) | Process for preparing 1-(acetylaminophenyl)-2-amino-propanone derivatives; derivatives thus obtained |